Bionano Genomics (BNGO) Payables (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Payables data on file, last reported at $15.2 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 22.39% year-over-year to $15.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (down 22.39% YoY), and the FY2025 full-year result was $15.6 million, down 43.02% from the prior year.
• Payables eased to $15.2 million in Q1 2026, from $15.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $80.2 million in Q4 2023 to a low of $6.6 million in Q1 2022.
• A 5-year average of $21.3 million and a median of $15.8 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables jumped 539.76% in 2023 and slumped 65.92% in 2024, its largest moves.
• Tracing BNGO's Payables over 5 years: stood at $12.5 million in 2022, then jumped by 539.76% to $80.2 million in 2023, then tumbled by 65.92% to $27.3 million in 2024, then sank by 43.02% to $15.6 million in 2025, then retreated by 2.28% to $15.2 million in 2026.
• Business Quant data shows BNGO's Payables at $15.2 million in Q1 2026, $15.6 million in Q4 2025, and $15.8 million in Q3 2025.